guanabenz and Disease Exacerbation

guanabenz has been researched along with Disease Exacerbation in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Antonini, G; Bella, ED; Bella, V; Borghero, G; Capasso, M; Caponnetto, C; Chiò, A; Corbo, M; Eleopra, R; Filosto, M; Giannini, F; Granieri, E; Lauria, G; Lunetta, C; Mandrioli, J; Mazzini, L; Messina, S; Monsurrò, MR; Mora, G; Riva, N; Rizzi, R; Siciliano, G; Silani, V; Simone, I; Sorarù, G; Tramacere, I; Volanti, P	1
Abbink, TEM; Bugiani, M; Dooves, S; Heine, VM; van der Knaap, MS; Wisse, LE	1
Brugarolas, P; Clayton, BL; Collins, TL; Kunjamma, RB; Miller, RH; Miller, SD; Podojil, JR; Popko, B; Robinson, AP; Way, SW; Zaremba, A	1
De Zutter, GS; Gill, A; Hatzipetros, T; Jiang, B; Kidd, JD; Levine, B; Lincecum, JM; Moreno, AJ; Perrin, S; Ping, Q; Tassinari, VR; Thompson, K; Vieira, FG; Wang, MZ	1

Trials

1 trial(s) available for guanabenz and Disease Exacerbation

Article	Year
Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). BMJ open, 2017, 08-11, Volume: 7, Issue:8 Topics: Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis Deficiencies	2017

Article

Year

Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).

BMJ open, 2017, 08-11, Volume: 7, Issue:8

Topics: Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis Deficiencies

2017

Other Studies

3 other study(ies) available for guanabenz and Disease Exacerbation

Article	Year
Bergmann glia translocation: a new disease marker for vanishing white matter identifies therapeutic effects of Guanabenz treatment. Neuropathology and applied neurobiology, 2018, Volume: 44, Issue:4 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Astrocytes; Biomarkers; Disease Models, Animal; Disease Progression; Guanabenz; Leukoencephalopathies; Mice; Phosphorylation; Treatment Outcome	2018
Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nature communications, 2015, Mar-13, Volume: 6 Topics: Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Survival; Cells, Cultured; Central Nervous System; Cerebellum; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Guanabenz; Inflammation; Interferon-gamma; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Rats; Rats, Sprague-Dawley; Stem Cells	2015
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. PloS one, 2015, Volume: 10, Issue:8 Topics: Adrenergic alpha-2 Receptor Agonists; Amyotrophic Lateral Sclerosis; Animals; Antihypertensive Agents; Disease Models, Animal; Disease Progression; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Fibroblasts; Guanabenz; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Degeneration; Phosphorylation; Protein Phosphatase 1; Superoxide Dismutase; Tunicamycin; Unfolded Protein Response	2015